Brickell Biotech

(BBI, NASDAQ)

$1.19

+$0.00
(+0.00%)
PE Ratio
0.00
EPS
-$9.55
Market Cap
$75M
52 Week Range
$0.47 - $3.44
Operating Margin
-968.39%
Dividend & Yield
$0.00 (0.00%)
Volume
NaN
Rev. per Share
$0.17

About Brickell Biotech

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. Its pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell Biotech, Inc. has a collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Earnings

News about Brickell Biotech

PR Newswire
last Monday
Thinking about buying stock in GameStop, Verb Technology, Brickell Biotech, Creative Realities, or Sorrento Therapeutics?
Hometown Weekly
11/25/2020
Brickell Biotech CFO resigns to fully commit to Edgewise Therapeutics
Benzinga
11/05/2020
The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping
The Lincolnian
10/25/2020
Brickell Biotech (NASDAQ:BBI) Shares Gap Down to $0.72
Benzinga
10/23/2020
Why Brickell Biotech's Stock Is Trading Lower Today
GlobeNewswire
10/23/2020
Brickell Biotech Announces Pricing of $15.0 Million Underwritten Public Offering
Longmont Times-Call
10/13/2020
Brickell Biotech to sell additional $15M worth of stock as critical clinical trial begins
Daily Camera
09/25/2020
Brickell Biotech’s flagship drug gets sale approval in Japan
Broomfield Enterprise
09/08/2020
Brickell Biotech to co-develop Japanese COVID-19 vaccine in Western Hemisphere
Seeking Alpha
09/08/2020
AnGes, Brickell Biotech collaborate for COVID-19 DNA vaccine candidate (NASDAQ:BBI)

Brickell Biotech

Type
Sector
Healthcare
Industry
Biotechnology
About kinfo
Kinfo is an app for DIY traders and investors. Kinfo tracks your trading performance and lets you compare measurable performance metrics against other traders. Kinfo works for day trading, swing trading and longer holding periods. By tracking portfolio performance kinfo allows traders to learn, find inspiration and gain confidence.
Get Social
Download the App

Trading involves significant risk of loss. It is not suitable for all investors and you should make sure you understand the risks involved, seeking independent advice if necessary.

Never risk more than you are willing to lose. Trading futures and other derivatives may cause losses that exceed deposits.

Hypothetical performance results have inherent limitations, some of which are described below. Kinfo makes no representation that any trading account will or is likely to achieve profits or losses like those shown. There are often sharp differences between hypothetical trading performance results and the actual results subsequently achieved by any trading program. Past results of advertised trading systems, profit statements, charts or any other representations are not indicative of future performance.

Kinfo is an educational site and is not a financial adviser or broker. All stocks, ETFs, commodities, Indices, Forex, Bonds, and other securities mentioned in our courses are for educational and illustrative purposes only. If you need professional investment advice, please consult a registered investment adviser. Futures and Options carry risk and may not be suitable for everyone.

Kinfo demonstrates specific advanced approaches (or methods). Any mention of Return of Investment percentages is only indicative of the potential of the strategy or the system and is not meant to signify any guaranteed returns.

Success in trading involves a range of human factors like decision making skills, adjustment skills, emotional control, and risk management and other psychological and behavioral parameters, all of which are completely in the hands of the individual. Trading involves significant risk of loss. It is not suitable for all investors.

Charts on kinfo provided by TradingView